Johnson & Johnson $JNJ Shares Sold by Compass Capital Management Inc.

Compass Capital Management Inc. lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 226,645 shares of the company’s stock after selling 10,073 shares during the period. Johnson & Johnson makes up about 3.8% of Compass Capital Management Inc.’s portfolio, making the stock its 6th biggest position. Compass Capital Management Inc.’s holdings in Johnson & Johnson were worth $60,002,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Jupiter Topco LLC purchased a new stake in shares of Johnson & Johnson during the second quarter valued at $1,967,399,000. Corient Private Wealth LP raised its stake in Johnson & Johnson by 127.3% in the 2nd quarter. Corient Private Wealth LP now owns 6,060,922 shares of the company’s stock worth $1,539,292,000 after acquiring an additional 3,393,981 shares during the last quarter. Wellington Management Group LLP lifted its position in Johnson & Johnson by 12.5% during the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after acquiring an additional 2,513,321 shares during the period. Amundi lifted its position in Johnson & Johnson by 17.5% during the 1st quarter. Amundi now owns 13,406,820 shares of the company’s stock worth $3,277,163,000 after acquiring an additional 2,001,139 shares during the period. Finally, Fisher Asset Management LLC grew its stake in Johnson & Johnson by 11.5% during the 3rd quarter. Fisher Asset Management LLC now owns 14,837,126 shares of the company’s stock valued at $3,927,981,000 after purchasing an additional 1,530,070 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on JNJ shares. Weiss Ratings cut Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a research note on Friday, October 23rd. Guggenheim reiterated a “buy” rating and issued a $287.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 7th. Royal Bank Of Canada reduced their price target on shares of Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a research report on Wednesday, October 14th. Bank of America reaffirmed a “neutral” rating and issued a $278.00 price objective on shares of Johnson & Johnson in a report on Tuesday, September 29th. Finally, Erste Group Bank lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $275.92.

Johnson & Johnson News Summary

These are some of the JNJ news items that stood out recently:

• Positive Sentiment: A Johnson & Johnson prostate-cancer drug combination is advancing into Phase 3, a meaningful clinical milestone that could strengthen the company’s oncology pipeline, although trial and commercial outcomes remain uncertain. Johnson & Johnson stock advances as prostate drug combo enters Phase 3
• Positive Sentiment: JNJ has risen 10.4% since its latest earnings report, and State Street’s Health Care SPDR added shares on Nov. 10. These reports suggest continued investor interest, though neither guarantees further gains. Johnson & Johnson Up 10.4% Since Last Earnings Report State Street Health Care SPDR Adds Johnson & Johnson
• Neutral Sentiment: J&J also led a $100 million funding round for Delix Therapeutics’ depression-drug development. This broadens its exposure to emerging psychiatric treatments, but clinical-stage programs carry substantial execution risk. Johnson & Johnson Backs New Cancer Device And Leads $100 Million Depression Bet

Johnson & Johnson Stock Up 0.8%

Shares of JNJ stock opened at $285.78 on Friday. Johnson & Johnson has a twelve month low of $193.55 and a twelve month high of $288.11. The stock has a market cap of $687.95 billion, a P/E ratio of 43.30, a P/E/G ratio of 2.80 and a beta of 0.22. The stock has a 50 day moving average of $266.97 and a 200 day moving average of $249.85. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. The business had revenue of $25.40 billion for the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business’s revenue was up 5.9% on a year-over-year basis. During the same quarter last year, the company earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts expect that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 81.21%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares in the company, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 61,669 shares of company stock valued at $16,898,386. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.